We previously established a model of acquired oxaliplatin resistance derived from the HCT116 oxaliplatin-sensitive cell line (HCT116S) and consisting in two resistant clones (HCT116R1, HCT116R2) and their total or partial revertants (HCT116Rev1 and HCT116Rev2, respectively). Using this cellular model, we explored the contribution of mitochondrial apoptosis and nuclear DNA to oxaliplatinmediated apoptosis induction and oxaliplatin resistance. We showed that the activity of oxaliplatin is mediated by the induction of Bax/Bak-dependent mitochondrial apoptosis and that oxaliplatin resistance is mediated by a defect in Bax/Bak activation correlating with a reduced loss of the mitochondrial transmembrane potential (DW m ). In addition, we observed that p53 only contributed marginally to oxaliplatin-induced cytotoxicity and was not involved in oxaliplatin resistance. Moreover and surprisingly, depletion of the nucleus in HCT116S cells did not abolish the oxaliplatin-induced DW m loss indicative of imminent apoptosis. Enucleation abolished the oxaliplatin resistance of HCT116R1 cells, while HCT116R2 cytoplasts conserved their resistant phenotype. Altogether, these data demonstrate that oxaliplatin exerts its cytotoxic effects by inducing mitochondrial apoptosis and that these effects can be initiated by interacting on other cellular structures than nuclear DNA. Resistance to oxaliplatin may imply both nuclear and cytoplasmic compartments.
Introduction
Oxaliplatin, a diaminocyclohexane-containing platinum, is now widely used in the treatment of advanced colorectal carcinoma in combination with 5-fluorouracil (Misset et al., 2000) . Indeed, the FDA approved oxaliplatin for the treatment of metastatic colorectal carcinoma in combination with 5-fluorouracil plus leucovorin as a first-line treatment in January 2004 (Ibrahim et al., 2004) . Even if the mode of action of oxaliplatin is assumed to be similar to that of cisplatin, mainly involving DNA crosslinking, oxaliplatin has a unique spectrum of activity. Thus, cytotoxic effects of oxaliplatin have been demonstrated in vitro and in vivo against a broad range of cancerous tissues including cisplatin-resistant cell lines or tumors (Raymond et al., 2002) .
While the mechanisms of the chemotherapy resistance arising against cisplatin are well studied, those accounting for oxaliplatin resistance are largely elusive. Cisplatin resistance simultaneously or alternatively involves the reduction in cisplatin accumulation, an increased repair of cisplatin adducts, the modulation of apoptotic pathways, a higher level of detoxification mediated by glutathione or metallothionein, the upregulation of transcription factors or the loss of p53 function (Boulikas and Vougiouka, 2003) . Oxaliplatin resistance can involve an increase in glutathione (El-akawi et al., 1996) , a reduction of drug accumulation and DNAplatinum adducts (Hector et al., 2001; Mishima et al., 2002) or a decrease in apoptosis susceptibility (Gourdier et al., 2002) . However, the resistance mechanisms against cisplatin and oxaliplatin overlap only in part. Thus, defects in the DNA mismatch repair system confer resistance against cisplatin but not against oxaliplatin (Fink et al., 1997) . Overexpression of the c-myc gene may predispose cells to die in response to oxaliplatin but not to cisplatin (Vekris et al., 2004) . That the chemotherapy resistance mechanisms among different platinum compounds are different is also indicated by the fact that oxaliplatin (in combination with gemcitabin) may achieve therapeutic responses in cisplatin-refractory germ cell cancer (Kollmannsberger et al., 2004) .
With the aim of studying the mechanisms of resistance to oxaliplatin, we previously established oxaliplatin-resistant clones from the HCT116 colon carcinoma cell line and demonstrated the role of apoptosis defect in the resistance to oxaliplatin (Gourdier et al., 2002) . In the present study, we dissect the relative contribution of proapoptotic signaling molecules such as p53, Bax and Bak to oxaliplatin resistance. Moreover, we report the unexpected finding that oxaliplatin can induce apoptosis even in the absence of nuclear DNA, and that resistance to oxaliplatin can be mediated by a purely cytoplasmic mechanism.
Results

Oxaliplatin-resistant cell lines and their revertants
By constant exposure of the colon carcinoma HCT116 cell line to increasing doses of oxaliplatin, we previously derived oxaliplatin-resistant cell clones, HCT116R1 and HCT116R2. The HCT116R2 clone was shown to be Bax-defective, due to a frameshift mutation (Gourdier et al., 2002) . Culturing HCT116R1 and HCT116R2 clones for 6 and 15 months, respectively, in the absence of oxaliplatin, also led us to derive two revertant cell lines that displayed some sensitivity to oxaliplatin. The reversal of the resistant phenotype was complete for the HCT116Rev1 cell line (derived from HCT116R1), while it was partial for HCT116Rev2, derived from HCT116R2 (Figure 1 ). In the present study, we have taken advantage of this panel of cell lines to address the mechanisms of oxaliplatin resistance and the reacquisition of oxaliplatin sensitivity. It should be noted that the term 'resistance' is truly applicable to HCT116R1 and HCT116R2 cells, because these cells have been selected for several months in oxaliplatin, used at doses that kill most (499%) of the parental cell line within B7 days. Since we found that HCT116R1 and HCT116R2 (but not HCT116Rev1) cells were more resistant to oxaliplatin-induced apoptosis, measured in short-term assays (1-3 days), as shown below, we believe that it is legitimate to attribute the long-term oxaliplatin resistance of HCT116R1 and HCT116R2 to disabled apoptosis.
Defective p53 signaling is not involved in oxaliplatin resistance
In response to oxaliplatin treatment, both the parental HCT116 cell line (which is HCT116-sensitive: HCT116S) and the two oxaliplatin-resistant cell lines HCT116R1 and HCT116R2 were capable of increasing the expression of a p53-inducible reporter gene (Figure 2a) . Accordingly, these three cell lines exhibited similar levels of induction of the p53 target p21 both at 48 h ( Figure 2b ) and in shorter experiments (not shown). In addition, we found that HCT116R1 (which, in contrast to HCT116R2, conserves an intact Bax gene) (Gourdier et al., 2002 ) exhibited a normal oxaliplatin-induced upregulation of the p53 target gene Bax, as detected by immunoblots (Figure 2b ). This suggests that the p53 pathway contributes to a similar extent to cell death induction in the oxaliplatin-sensitive and resistant cells. Accordingly, addition of cyclic pifithrin-a, a potent chemical inhibitor of the transactivating function of p53 (Komarov et al., 1999) , elevated the IC 50 (the concentration of drug required to inhibit cell growth by 50%) of oxaliplatin in all three cell lines by a factor of 2.170.4 in HCT116S, 1.770.2 in HCT116R1 and 3.371.0 in HCT116R2 (Figure 2c ), again suggesting that p53 was functional irrespective of the susceptibility/resistance status of the cell line. This significant, although limited effect of chemical p53 inhibition is similar to the one obtained after the knockout of the p53 gene (HCT116 p53
) in the parental cell line, where the factor of protection is 2.170.2 (Figure 2d ). This limited level of resistance, by a factor of approximately 2 (Figure 2d) , contrasts with the marked resistance of the HCT116 p53 þ / þ sublines R1 and R2 (by a factor of 28 and 68, respectively) ( Figure 1 ). In conclusion, it appears that the p53 pathway only plays a minor role in oxaliplatininduced cytotoxicity, and that p53 is not involved in oxaliplatin resistance, at least in this panel of cell lines.
Delayed activation of Bax and Bak in oxaliplatin resistance
To directly assess to which extent the Bax defect, identified in the Bax-mutated HCT116R2 clone, contributes to the oxaliplatin resistance, we investigated the impact of the Bax knockout (HCT116 Bax À/À ) (Zhang et al., 2000) . The ablation of Bax conferred an oxaliplatin resistance limited to a factor of 2.070.3 (Figure 3 ), suggesting that this mutation alone may not account for the oxaliplatin resistance of HCT116R2. Accordingly, the revertant HCT116Rev2 line has lost a major part of the resistance capacity of HCT116R2 while it still carries the Bax mutation. These data indicate that the Bax defect cannot be the only cause of the HCT116R2 resistance. HCT116R1 cells exhibited a similar oxaliplatin induction of Bax protein as parental HCT116S cells (Figure 2b ). We thus determined the kinetics of Bax activation in these cell lines, using immunofluorescence staining with an antibody that recognizes the N-terminus of Bax only when it is exposed and when Bax is in its apoptotic conformation (Nechushtan et al., 1999) . HCT116S cells manifested a progressive activation of Bax during oxaliplatin treatment. In contrast, HCT116R1 cells showed a delayed activation of Bax (Figure 4a, b) . We also investigated the conformational activation of the proapoptotic Bcl-2 Figure 1 Oxaliplatin-resistant cells and their revertants. For each clone previously derived from the HCT116 cell line, the sensitivity to oxaliplatin was evaluated by determining the IC 50 value using the WST-1 colorimetric assay, measured at 48 h. Results are expressed as mean IC 50 7s.d. (n ¼ 3). The relative resistance (in parenthesis) corresponds to the ratio of each IC 50 over that of the sensitive HCT116/S cell line Oxaliplatin resistance I Gourdier et al multidomain protein Bak (which is not a p53 target) (Griffiths et al., 1999) which, in some cases, is functionally overlapping with Bax (Wei et al., 2001; Zong et al., 2001) . The two resistant HCT116 clones had a delayed activation of Bak, and this delay was lost in the two HCT116 revertants HCT116Rev1 and HCT116Rev2 (Figure 4c , d). Both Bax and Bak, once activated, are known to cause a severe mitochondrial dysfunction, which precipitates the apoptotic cascade (Marzo et al., 1998; Narita et al., 1998; Wei et al., 2001) . One of the manifestations of this mitochondrial dysfunction is the reduction of the mitochondrial transmembrane potential (DC m ). As to be expected from the defective activation of Bax and Bak, both resistant cell lines (but not their revertants) manifested a delayed or absent DC m loss when treated with oxaliplatin ( Figure  5a , b). Another manifestation of apoptotic mitochondrial change is the release of cytochrome c. Upon oxaliplatin treatment, HCT116 R1 and R2 cells exhibited a reduced cytochrome c release from mitochondria, as compared to parental HCT116S cells ( Figure 5c ). In conclusion, it appears that the oxaliplatin resistance of HCT116 cells operates at the level or upstream of mitochondria.
Combined contribution of Bax and Bak to oxaliplatin-induced apoptosis
To directly assess the relative contribution of the proapoptotic Bcl-2 multidomain family proteins to oxaliplatin-mediated cytotoxicity and to oxaliplatin resistance, we selectively knocked down Bax and Bak expression by small interfering RNA ( Figure 6a ). While Bax knockdown increased the resistance of parental HCT116S cells (Figure 6b ) as does the Bax knockout (see above in Figure 3 ), it appears that the knockdown of Bak had no effect ( Figure 6b ). Similar results were obtained in the HCT116R1 cell line, in which Bax knockdown conferred some resistance, while Bak knockdown had no significant effect ( Figure 6c ). These results show that the downmodulation of Bak alone cannot be the limiting factor of oxaliplatin resistance. In the Bax-deficient HCT116R2 clone, however, the Bak knockdown conferred additional apoptosis resistance (Figure 6d ). These data together with those from Figure 4 argue in favor of a combined participation of Bax and Bak in oxaliplatin-induced cellular response.
Oxaliplatin activity in anucleate cells
Although oxaliplatin was reported as a DNA-damaging agent (Reardon et al., 1999; Hector et al., 2001; Raymond et al., 2002) , its activity appeared in our (Figures 3-6 ). We thus wondered whether oxaliplatin might target other cellular structures than nuclear DNA. We depleted HCT116 cells from their nuclear DNA by enucleation of cytochalasin B-pretreated cells on a Ficoll gradient (Jacobson et al., 1994; Schulze-Osthoff et al., 1994; Castedo et al., 1996) . As shown in Figure 7 , these anucleate cells (also called 'cytoplasts'), which fail to incorporate the chromatin stain Hoechst 33342, were still able to manifest an oxaliplatin-induced DC m loss indicative of imminent apoptosis (Debatin et al., 2002) . Moreover, this response to oxaliplatin treatment was shown to be dose dependent (Figure 8) . As a control, irinotecan (a cytotoxic drug targeting topoisomerase 1 in the nucleus) had no effect on the cytoplasts (Figure 8a ). These results imply that oxaliplatin can elicit apoptosis by acting on other cellular structures than nuclear DNA.
Resistance to oxaliplatin in anucleate cells
To determine whether the oxaliplatin resistance of HCT116R1 and HCT116R2 clones would be tied to the presence of the nucleus, these resistant cell lines were enucleated. Surprisingly, cytoplasts from HCT116R1 cells lost their status of oxaliplatin resistance, visible in intact cells (Figure 8b ), upon enucleation (Figure 8a ).
Thus, HCT116R1 cytoplasts were as sensitive to oxaliplatin treatment as were cytoplasts from HCT116S parental cells. In strict contrast, cytoplasts from HCT116R2 cells maintained apoptosis resistance upon oxaliplatin treatment (Figure 8 ). These data provide formal proof that the mechanisms of resistance to oxaliplatin are fundamentally different between HCT116R1 and HCT116R2 cells. They also suggest that apoptosis resistance could involve both the nuclear and the cytoplasmic compartments.
Discussion
We have demonstrated in this study that the activity of oxaliplatin is mediated by the induction of Bax/ Bak-dependent mitochondrial apoptosis (Figures 4, 5 and 6b). We previously pointed out a defect in mitochondrial apoptosis associated with resistance to oxaliplatin. A mutation in Bax gene, leading to the loss of Bax expression, was discovered in the most resistant HCT116R2 cell clone but not in HCT116R1 (Gourdier et al., 2002) . In the present work, we showed that the Bax gene mutation, persisting in HCT116Rev2 cells which have lost a major part of their resistance (Figure 1) , is not sufficient to explain the HCT116R2 resistance and that a Bax defect seems to be a minor player in oxaliplatin resistance (Figure 3) . However, the Oxaliplatin resistance I Gourdier et al absence of Bak activation in HCT116R2 (deficient for Bax) or of both Bax and Bak activation in HCT116R1 could explain the failure to activate mitochondrial apoptosis and consequently the observed resistance to oxaliplatin (Figures 4 and 5) . In addition, RNA interference experiments reinforced the hypothesis of a combined contribution of Bax and Bak inactivation to oxaliplatin-induced cellular response (Figure 6 ). A functional defect in such Bcl-2 family proteins, which control the induction of mitochondrial apoptosis, seems to be a critical mechanism in the occurrence of oxaliplatin resistance.
Oxaliplatin is well known as a nuclear DNA-damaging agent. Oxaliplatin forms covalent platinum-DNA adducts similar to those produced by cisplatin 
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Cytoplasts (Woynarowski et al., 1998) . A major difference between the two drugs consists in the fact that oxaliplatin is more cytotoxic than cisplatin when an equivalent level of DNA lesions is generated (Woynarowski et al., 2000) . Surprisingly, in our study, the activity of oxaliplatin and the resistance to oxaliplatin appeared to be largely p53 independent (Figure 2) . Moreover, after removal of the nucleus from HCT116S cells, the resulting cytoplasts maintained their susceptibility to the oxaliplatinmediated DC m loss indicative of imminent apoptosis (Figure 8 ). Upon removal of the nucleus, HCT116R1 cytoplasts became susceptible to oxaliplatin-mediated apoptosis, while HCT116R2 cytoplasts remained oxaliplatin resistant (Figure 8 ), indicating that these two clones had developed two fundamentally distinct mechanisms of oxaliplatin resistance (Figures 7 and 8) . We have demonstrated here for the first time that the nucleus is not the only target of oxaliplatin activity. However, as far as oxaliplatin resistance is concerned, it appears that the nucleus can contain resistance factors and/or induce their transcription, as indicated by the enucleation of HCT116R1 cells. It has been suggested that the interaction of oxaliplatin with other cellular structures than DNA (like proteins) could explain the differential cytotoxic effect of oxaliplatin and cisplatin for a similar level of platinum-DNA adducts (Woynarowski et al., 2000) . Nonetheless, it has recently been reported that cisplatin could also induce the apoptotic signaling independently from the nucleus (Mandic et al., 2003) . The data obtained on HCT116R1, HCT116R2 and their revertants suggest that there are several layers of resistance mechanisms that contribute, presumably as a result of a multistep selection process, to abolish oxaliplatin toxicity. The HCT116R1 line is likely to lack stable mutations, as indicated by the fact that it can revert to full oxaliplatin sensitivity upon prolonged withdrawal of the drug (Figure 1) . A yet-to-be-defined nuclear element determines the oxaliplatin resistance of HCT116R1, as suggested by the observation that removal of the nucleus abolishes its chemoresistance (Figure 8) . In strict contrast, it is likely that HCT116R2 has accumulated several stable mutations that confer oxaliplatin resistance, one that affects the Bax gene (Figure 2 ; Gourdier et al., 2002) and one or several additional ones whose nature is elusive. Thus, HCT116R2 does not revert to full oxaliplatin sensitivity (Figure 1 ) and remains fully apoptosis resistant upon removal of the nucleus.
We anticipate from our work that the future discovery of the cytosolic target(s) of oxaliplatin could unravel the molecular bases of the anticancer action of oxaliplatin and pave the way to novel strategies for reversing chemoresistance.
Materials and methods
Cell lines and reagents
Cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum and 2 mM glutamine without antibiotics. The three cell lines HCT116/S, HCT116/R1 and HCT116/R2 were derived from the HCT116 cell line as previously described (Gourdier et al., 2002) . Resistant cells were maintained in the presence of 5 and 10 mM oxaliplatin, respectively, for R1 and R2 cells. Before each experiment, resistant cells were cultured without oxaliplatin for a week. The two revertant variants HCT116/Rev1 and HCT116/Rev2 were obtained by culture in the absence of oxaliplatin for 6 and 15 months, respectively. The HCT116/p53 À/À and HCT116/ Bax À/À cell lines, as well as their controls, were kindly provided by Dr B Vogelstein (Bunz et al., 1999; Zhang et al., 2000) . pGL2B-mdm2-luciferase and pTKRL plasmids were a generous gift from Dr P Roux. Cyclic pifithrin-a were purchased from Calbiochem., while oxaliplatin was from Sanofi and irinotecan from Aventis.
Drug sensitivity assay
Growth inhibition assays were performed by seeding 4000 cells per well in 96-well plates. After a 24 h rest for cell attachment, drugs were added in dilutions series during 48 h, with each concentration in triplicate. Cytotoxicity measurements were carried out using the WST-1 colorimetric assay (Boehringer Mannheim) according to the manufacturer's recommendations.
Luciferase assay p53 transactivation was measured using the dual-luciferase assay system from Promega. Cells (5 Â 10 4 ) were seeded onto 12-well plates and transfected 24 h later in OptiMEM containing 0.4 mg of DNA (0.32 mg of pGL2B-mdm2-luciferase plasmid and 0.08 mg of pTKRL plasmid) using 0.3 ml of lipofectamine (Gibco-BRL) for 4 h. Cells were then rinsed with RPMI supplemented with 10% fetal bovine serum and 2 mM glutamine and treated or not with oxaliplatin for 20 h before lysis with the passive lysis buffer (PLB; Promega). Luciferase activity was measured following the Dual-Luciferase Reporter Assay Protocol as recommended by Promega, using a luminometer fitted with two injectors (Berthold).
Western blotting analysis
Subconfluent monolayers of cells were trypsinized, washed twice in PBS and lysed in triton buffer (50 mM Nacl, 5 mM EDTA pH 7.5, 50 mM NaF, 1% Triton X-100, 1 mM DTT, 1 mM PMSF, 50 mM Tris.HCl pH 7.5) in the presence of protease inhibitors for 1 h on ice. Proteins concentrations were determined using the Biorad D C protein assay. Cells lysates were diluted in Laemmli buffer (Bromophenol Blue, 0.7 M bmercaptoethanol, 2% SDS, 10% glycerol and 0.5 M Tris.HCl). The extracts were sonicated, and boiled for 5 min. In total, 30 mg of cells lysate per lane were separated by 12% SDS-PAGE and were transferred onto nitrocellulose membrane by electroblotting. Membranes were blocked 50 min at room temperature in PBS-0.1% Tween 20 containing 5% dried nonfat milk, incubated for 2 h at room temperature with primary antibody anti-Bax polyclonal rabbit antibody (Upstate), anti-Bak polyclonal rabbit antibody (BD PharMingen), anti-p21 monoclonal antibody (PharMingen) or anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) monoclonal mouse antibody (Chemicon), and washed in PBS-0.1% Tween 20. Blots were then incubated for 1 h at room temperature in blocking buffer with the corresponding peroxidase-conjugated secondary anti-mouse or anti-rabbit IgG antibody (Southern Biotechnology Associates) and washed again. Bound complexes were detected using the SuperSignal West Pico chemiluminescent substrate (Pierce).
Detection of apoptosis-associated mitochondrial alterations
Cells (0.5-1 Â 10 6 cells per condition) were treated with 15 mM oxaliplatin for 12, 24 or 48 h. After trypsinization, cells were fixed in 0.25% paraformaldehyde in PBS for 5 min, washed in PBS three times and incubated with 1 : 100 anti-Bax antibody (clone 6A7, BD Biosciences) or anti-Bak antibody (clone TC100, Oncogene) in 100 mg/ml digitonin (for anti-Bax) or 0.05% saponin (for anti-Bak) diluted in PBS-1% BSA for 30 min. After being washed three times in PBS-1% BSA, cells were incubated with 1 : 250 FITC-conjugated secondary antimouse antibody diluted in PBS-1% BSA for 30 min (Poncet et al., 2004) . After two washes, cells were resuspended in PBS and analysed on a FACS Vantage cytofluorometer (Becton Dickinson). DC m was determined by the fluorochrome TMRM (Molecular Probes) and the subcellular redistribution of cytochrome c was measured by immunofluorescence, as described . For each condition, 0.5-1 Â 10 6 cells were incubated with 250 nM TMRM at 371C for 15 min and immediately subjected to cytofluorometric analysis.
Preparation of cytoplasts
Trypsinized cells (10-50 Â 10 6 per cell line) were incubated in 3 ml of complete medium in the presence of 7.5 mg/ml of cytochalasin B and 40 U/ml of DNAse for 45 min at 371C. This cell suspension was layered onto a discontinuous Ficoll s (Pharmacia) density gradient (3 ml of 55%, 1 ml of 90% and 3 ml of 100% Ficoll in complete medium containing 7.5 mg/ml cytochalasin B and 40 U/ml DNAse; gradients were prepared in ultracentrifuge tubes and pre-equilibrated at 371C in a CO 2 incubator overnight). Gradients containing cell suspensions were centrifugated in a prewarmed SW41 Beckman rotor at 25 000 r.p.m. for 20 min at 321C. The cytoplasts-enriched fraction was collected from the interface between 55 and 90% Ficoll layers, washed in complete RPMI medium, and incubated overnight at 371C, before oxaliplatin or irinotecan were added for 24 h. Then the cells were labeled with 250 nM TMRM and 1 mg/ml Hoechst 33342 for 15 min at 371C, followed by cytofluorometry. Cells with nuclei contaminating the cytoplasts-enriched fraction were excluded by gating on the Hoechst 33342-negative population.
RNA interference
Selected oligonucleotides RNAs were synthesized, HPLCpurified and annealed into siRNA duplexes (Proligo). RNA interference of Bax and Bak expression was performed using specific siRNA sequences for Bax gene (sense strand, 5 0 -rgrgUrgrCrCrgrgrArArCUrgrAUrCrArgrATT-3 0 or for Bak gene (sense strand 5 0 UrgrgUrCrCrCrAUrCrCUrgrArArCr gUrgTT-3 0 ) (Perfettini et al., 2004) . For transfection, cells were cultured in six-well plates (5 Â 10 4 cells per well) for 24 h and then transfected overnight with 1.68 mg siRNA formulated into liposomes with 6 ml oligofectamine (Invitrogen). Controls were obtained by transfection of empty liposomes in the same conditions than siRNA-transfected cells. At 3 days after transfection, cells were subjected to oxaliplatin treatment in 96-well plates for 48 h as described above.
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